Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review
- 2 May 2021
- journal article
- review article
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (3) , 1182-1194
Abstract
Objectives This work aimed to report the demographic and clinical characteristics of two new cases with non-paraneoplastic anti-Hu-associated gut motility impairment, and perform a thorough revision covering anti-Hu-associated paraneoplastic (PGID) and non-paraneoplastic (nPGID) gastrointestinal dysmotility. Background Several case series have clearly established a relationship between certain type of cancers, the development of circulating anti-Hu antibodies, and the concomitant usually severe gastrointestinal dysmotility; in contrast, a few studies focused on anti-Hu-associated nPGID. Methods We searched for studies regarding anti-Hu-associated gastrointestinal manifestations and extracted data concerning clinical characteristics of patients, including specific demographic, oncological, neurological, gastrointestinal, histological, and treatment response features. Results Forty-nine articles with a total of 59 cases of anti-Hu-associated gastrointestinal dysmotility were analyzed. The patients’ age at symptom onset significantly differed between PGID and nPGID (median 61 vs 31 years, p < 0.001). Most cancers (95%) in PGID were detected within 24 months from the beginning of gastrointestinal symptoms. The impairment of gastrointestinal motility was generalized (i.e., involving the whole gut) in 59.3% of patients, with no significant differences between PGID vs nPGID group. nPGID patients showed a better response to immunomodulatory/immunosuppressive treatment and a longer life expectancy. Conclusions Anti-Hu-associated gastrointestinal dysmotility covers a wide clinical spectrum. Patients with otherwise unexplained gastrointestinal dysmotility, especially when associated with other neurological symptoms, should be tested for anti-Hu antibodies regardless age of onset and disease duration. Compared to PGID, nPGID occurs in younger patients with a long duration of disease.Keywords
This publication has 59 references indexed in Scilit:
- Immunopathology of autoantibody-associated encephalitides: clues for pathogenesisBrain, 2012
- Paraneoplastic Gastrointestinal Dysmotility: When to Consider and How to DiagnoseGastroenterology Clinics of North America, 2011
- A novel approach to paraneoplastic intestinal pseudo-obstructionSupportive Care in Cancer, 2011
- Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal DysmotilityClinical Gastroenterology and Hepatology, 2008
- Pseudo-obstruction intestinale chronique et syndrome des anti-Hu : 13 ans de suivi sans apparition de néoplasieGastroentérologie Clinique Et Biologique, 2008
- Obstipation as a paraneoplastic presentation of small cell lung cancer: case report and literature reviewNeurogastroenterology & Motility, 2005
- Intestinal Pseudoobstruction as a Paraneoplastic Syndrome in GanglioneuroblastomaEuropean Journal of Pediatric Surgery, 2002
- Loss of interstitial cells and a fibromuscular layer on the luminal side of the colonic circular muscle presenting as megacolon in an adult patientGut, 1999
- Pseudo-occlusion intestinale et neuronopathie sensitive paranéoplasiques révélatrices d'un cancer bronchique à petites cellulesLa Revue de Médecine Interne, 1997
- Intestinal pseudo-obstruction, type 1 anti-neuronal nuclear antibodies and small-cell carcinoma of the lungJournal of Gastroenterology and Hepatology, 1993